MyPath Melanoma is a 23-gene expression profile test that provides objective information to aid in the diagnosis and treatment decision making of challenging melanocytic lesions, as well as when melanoma cannot be ruled out.
1. Diagnostic support in challenging histopathologic scenarios
MyPath Melanoma is particularly useful in equivocal cases involving dermoscopic concern and the following histopathologic findings:
- Moderate to severely dysplastic nevi
- Atypical intraepidermal melanocytic proliferations (AIMPs)
- Atypical junctional melanocytic proliferations (AJMPs)
- Cases where melanoma cannot be definitively ruled out
- Pathology reports with non-definitive language such as “unusual features” or “suspicious for melanoma in situ (MIS)”
2. Clinical decision-making in cases of dermoscopy-pathology discordance
When dermoscopic findings raise concern but histopathology is inconclusive, MyPath Melanoma can support a more objective and individualized treatment plan:
Malignant MyPath Melanoma Result: Consider an excision with a 5mm surgical margin when the result is suggestive of malignancy.
3. Management of ambiguous lesions in cosmetically sensitive areas
MyPath Melanoma has a high negative predictive value (NPV) and is particularly valuable when managing melanocytic lesions in cosmetically sensitive regions (e.g., the face, ears ):
- Benign MyPath Melanoma Result: Consider deferring further surgical intervention and instead monitor the biopsy scar site with longitudinal digital dermoscopy imaging. At follow-up, if dermoscopic changes are observed (e.g., new pigmentation, round structures, blue-white veil, or other concerning features), consider re-excision with a 5mm margin.
